dokumendiregister.ee
OtsingAsutusedMCP
Otsing›Terviseamet
Väljaminev dokumentAvalik

Vastuskiri

Terviseamet · 7. november 2024
Viit
11.3-3/24/10271-2
Registreeritud
7. november 2024
Dokumendi liik
Väljaminev dokument
Adressaat
Fortrea Development Ltd
Saabumis/saatmisviis
vastutaja nimeliselt e-posti aadressilt välja saadetud
Funktsioon
11.3 SULETUD 2025 Meditsiiniseadmete alane koostöö Euroopa komisjoni, sõsarasutuste, ministeeriumide ja teiste ametite/inspektsioonidega
Sari
11.3-3 Üldine kirjavahetus (Koostöö riigiasutustega (ministeeriumid, ametid, inspektsioonid, jms)
Toimik
11.3-3/2024
Vastutaja
Merili Saar-Abroi (TA, Peadirektori asetäitja (1) vastutusvaldkond, Meditsiiniseadmete osakond)

Failid

  • 📎Vs_ Safety Reporting Requirements in the context of Medical Device Clinical Trials in Estonia query .msg121 KB

Sisu (failidest)

Saatja: Meditsiiniseadmed (Medical Devices) </O=SOTSIAALMINISTEERIUM/OU=FIRST ADMINISTRATIVE GROUP/CN=RECIPIENTS/CN=MSOC5ACD8534204CFDEC17D568B7204AE5C891A7D> Saaja: Chevalier, Aleksandra Teema: Vs: Safety Reporting Requirements in the context of Medical Device Clinical Trials in Estonia query Dear Ms. Chevalier The provided information seems to be correct. In general, Estonian Medical Devices Act does not specify any safety reporting requirements. All safety reporting should be prepared in accordance with the Regulation (EU) 2017/745 (MDR) and following the guidance MDCG 2020-10/1. In case of any further questions, please do not hesitate to contact us again. All the best, Merili Saar-Abroi Chief Specialist Department of Medical Devices Phone +372 554 3041 [email protected]<mailto:[email protected]> | [email protected]<mailto:[email protected]> [cid:[email protected]] Terviseamet | Health Board +372 794 3500 [email protected]<mailto:[email protected]> www.terviseamet.ee<http://www.terviseamet.ee/> Paldiski mnt 81, 10614 Tallinn This e-mail is confidential and meant for use by the person named in the letterhead. Any use in any way or copying of it by a person not marked as the addressee thereof is prohibited. If you have got this e-mail by mistake, please notify of it the sender without delay and delete the received e-mail together with all its attachments. Saatja: Chevalier, Aleksandra <[email protected]> Saatmisaeg: reede, 11. oktoober 2024 12:37 Adressaat: TA Info <[email protected]> Teema: Safety Reporting Requirements in the context of Medical Device Clinical Trials in Estonia query Good morning, Hope this email finds you well. Could you please confirm if the provided information (in green color) related to the Safety Reporting requirements in the context of Medical Device Clinical Trials in Estonia is up to date. · Domestic SADEs occurring within study (yes/no)? Yes · Foreign SADEs occurring within study (yes/no)? Yes · SADEs from other studies with same study device / Cross-reports (yes/no)? No o SADE Reporting Form: Clinical Investigation Summary Safety Report Form o SADE Reporting Method: electronic o SADE Reporting Format: electronic Electronic reporting destination: [email protected]<mailto:[email protected]> · Additional/Exceptions to expedited 7/15 SADE reports? (Yes/No) if yes, please see special reporting requirements: Yes - Serious public health threat: 2 days. Death or UNANTICIPATED serious deterioration in state of health: 7 days. Others: 30 days · Periodic Line Listing required? (Yes/no) if yes, please confirm: No o Frequency for Line Listing: NA o Reporting Timeline for Periodic Line Listing (days after DLP) NA o Periodic Line Listing Reporting Method (e.g. e-mail, N/A, etc.) NA o Periodic Line Listing Format: NA Destination for electronic Line Listing: NA · Annual Report required? (yes/no) if yes, please confirm: No o Reporting Timeline for Annual Report (days after DLP) NA o Annual Report Reporting Method (e.g. courier, CESP, email etc) NA o Annual Report Reporting Format (e.g. paper, CD-ROM, pdf, eCTD etc) NA Destination for electronic Annual Report submission: NA * Periodic Report Special reporting requirements: NA o Translation required for safety reports? No * Translation requirements - Language and report/information to be translated? (if yes, please specify the language) NA Thank you in advance for your time and support. Best Regards, Aleksandra Chevalier, MPharm Drug Safety Associate, Drug Safety E: [email protected]<mailto:[email protected]> fortrea.com Fortrea Development Ltd [B04571E5] ________________________________ Fortrea This e-mail may contain confidential, proprietary, or protected information - including protected health information - that is meant to be viewed only by the intended recipient or company. Any unauthorized review, use, copying, downloading or disclosure is strictly prohibited. If this e-mail is not intended for you, or if you have received this e-mail in error, please notify the sender immediately. Do not forward it to any further recipients and permanently delete this e-mail and all attachments. If you have questions or concerns, please see our privacy policy on Fortrea.com
Allikas: Terviseamet dokumendiregister →
dokumendiregister.eeAsutusedEesti avalike dokumendiregistrite otsing · nimistu.ee andmetel